Cargando…

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program

BACKGROUND: Erdafitinib is the first targeted therapy approved for the treatment of patients with metastatic urothelial carcinoma (mUC). Approval was based on a phase II single-arm trial that demonstrated significant activity of erdafitinib in patients with tumors harboring FGFR2/3 alterations. In B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monteiro, Fernando Sabino M., Silva, Adriano Gonçalves e, Gomes, Andrea Juliana P. de S., Dutra, Carolina, Ferreira, Naira Oliveira, Mariano, Rodrigo Coutinho, Schutz, Fabio A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135201/ https://www.ncbi.nlm.nih.gov/pubmed/34046088 http://dx.doi.org/10.1177/17588359211015499

Ejemplares similares

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2022)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
por: Fontes, Mariane S, et al.
Publicado: (2022)

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
por: Zheng, Xinyi, et al.
Publicado: (2023)

Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
por: Bloudek, Lisa, et al.
Publicado: (2023)

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib
por: Deutsch, Alana, et al.
Publicado: (2020)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Changes in CoQ(10)/Lipids Ratio, Oxidative Stress, and Coenzyme Q(10) during First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma (mUC)
por: Palacka, Patrik, et al.
Publicado: (2022)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report
por: Ding, Xinjia, et al.
Publicado: (2021)

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
por: Dosne, Anne‐Gaëlle, et al.
Publicado: (2021)

Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma
por: Lawson‐Michod, Katherine A., et al.
Publicado: (2022)

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
por: Bergmann, Sonja, et al.
Publicado: (2020)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment
por: Wang, Songbai, et al.
Publicado: (2020)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

Implementing Cisco UCS solutions
por: Ahmed, Farhan, et al.
Publicado: (2013)

High Density UC Properties
por: Luigi B. TecchioLaboratori Nazionali di Legnaro
Publicado: (05/1)

UC Updatable Databases and Applications
por: Damodaran, Aditya, et al.
Publicado: (2020)

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
por: Houédé, N., et al.
Publicado: (2016)

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
por: Pham, Chi, et al.
Publicado: (2023)

UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines
por: Corrà, Fabio, et al.
Publicado: (2021)

The ENCODE Project at UC Santa Cruz
por: Thomas, Daryl J., et al.
Publicado: (2007)

Variation resources at UC Santa Cruz
por: Thomas, Daryl J., et al.
Publicado: (2007)

Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
por: Meng, Xinmin, et al.
Publicado: (2022)

Analysis of Long Non-Coding RNA (lncRNA) uc.38 and uc.63 Expression in Breast Carcinoma Patients
por: Zadrożna-Nowak, Anna, et al.
Publicado: (2022)

Mucin (MUC) Family Influence on Acute Lymphoblastic Leukemia in Cancer and Non-Cancer Native American Populations from the Brazilian Amazon
por: de Alcântara, Angélica Leite, et al.
Publicado: (2022)

UC Santa Cruz Workshop on Galactic Haloes
por: Zaritsky, D
Publicado: (1997)

Draft Genome Sequence of Tombunodavirus UC1
por: Greninger, Alexander L., et al.
Publicado: (2015)

Dp-ucMGP as a Biomarker in Sarcopenia
por: Schweighofer, Natascha, et al.
Publicado: (2022)

Implementing Cisco UCS solutions: a hands-on guide to deploy, manage, troubleshoot and automate Cisco UCS solutions in the data center
por: Modi, Anuj, et al.
Publicado: (2017)

Women who live in mining on the French-Brazilian border: daily challenges
por: Mendes, Lise Maria Carvalho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aji4dvnibduqvfr40a517kgj5b